ALFA Finder| Revenue growth | 32% YoY growth; US up 43%, India up 13.9%. |
|---|---|
| Margins | EBITDA margins at 30%; full-year guidance steady at 25%. |
| Demand visibility | Strong chronic segment demand in India; US volume growth healthy. |
| Management confidence | Confident but cautious, flagging near-term competitive headwinds in the US. |
Growth
Revenue grew 32% YoY; US business rose 43% and India 13.9%. Gross margins improved to 74.6% on better product mix.
Outlook
Guided for high single-digit revenue growth and approximately 25% EBITDA margins for full year FY27.
Risks
Near-term moderation in US performance due to competitive entry in Tolevapton and Mirabegron; Geopolitical uncertainty impacts.
Last quarter's promises, checked
Delivered
- Guided 27-28% EBITDA margin → delivered 29.7% (= BEAT)
- Guided high single-digit revenue growth → delivered 23% (= BEAT)
- Targeted chronic segment share 66% → delivered 66% (= BEAT)
Partly delivered
- Guided ETR 22.1% → delivered 30% in Q1 FY27 (= MISS)
Earnings Call Transcript filed with BSE, NSE: LUPIN. Summary written with AI assistance from the document.
Lupin Ltd: key numbers
- Share price
- ₹2,023.40
- Market cap
- ₹92,529 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.8×Sector 43.8×
- Promoter holding
- 46.84%-0.01% QoQ
- FII holding
- 23.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Earnings Call Transcript: Key Takeaways
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Lupin Investor Presentation: Key Takeaways
Q2 FY27 net sales ₹77,855mn (+14% YoY); EBITDA ₹19,574mn, margin 25.1% (vs 31.3%); net income ₹11,553mn (-21.8% YoY). US pressured by competition/LOE.
Lupin Management Change
Lupin appointed Akhil Gupta as an Additional and Independent Director effective 3 November 2026, for five years to 2031. The appointment is subject to shareholder approval.
Lupin Q2 FY27 Results: Net Profit ₹1,155 Cr, Down 22.2% YoY
Lupin Ltd reported revenue from operations of ₹7,827 Cr (+11.1% YoY) and net profit of ₹1,155 Cr (-22.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,155 Cr · -22.2% YoY
Lupin Product Launch
Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.